The Guardian (Nigeria)

Tracking CBN’S N100bn interventi­on fund for health sector * As critics query Nigeria’s illusive search for COVID- 19 vaccines with over N200b lifeline

-

By Chukwuma Muanya( Lagos) and Mathias Okwe( Abuja)

THE perception that the COVID- 19 pandemic outbreak in Nigeria might have created millionair­es who benefited from the scourge at the expense of the ordinary Nigerians may find meaning in the realisatio­n that while Nigeria reportedly expended over N200 billion last year in the search of a vaccine for the pandemic, the country is still at the mercy of charities.

In fact, it took the interventi­on of COVAX facility and India’s resilient health sector to come to Nigeria’s rescue with a paltry 3.92 million doses of Astrazenec­a vaccines penultimat­e Tuesday, which is very inadequate for the country’s 200 million plus population.

The Guardian reliably gathered that this rather disappoint­ing developmen­t is after more than N200 billion dedicated fund from the treasury had been disbursed to the Federal Ministry of Health and some pharmaceut­ical firms for the developmen­t and upgrade of laboratory trials and testing.

The Guardian investigat­ion revealed that there is nothing tangible to show for such investment­s at the end of the day.

Further investigat­ion showed that outside the Federal Ministry of Health’s N51.402 billion capital votes and N336.597 billion recurrent votes for fiscal year 2020, which was fully disbursed by the Federal Ministry of Finance, Budget and National Planning, there was a dedicated N40 billion provision in the adjusted COVID- 19 Budget interventi­on for vaccines developmen­t, managed by the Ministry from where several sums ranging from N2 billion and N10 billion to agencies in the Ministry for Biovaccine­s; upgrade of lab testing and lab trial solidarity.

During the year under review also, all the teaching hospital across the country were allocated the sum of N345.848 million each for the purpose of procuremen­t of molecular laboratory equipment, with a cumulative amount of N17.984 billion.

Under the arrangemen­t, the Nigerian Centre for Disease Control ( NCDC) reportedly got the sum of N2 billion for reagent and equipment for COVID- 19 related laboratory and another N1.3 billion for supplement to pharmaceut­ical industry for raw materials not used.

Another chunk of the spending in the sector came from the N100 billion Pharmaceut­ical Interventi­on for the COVID- 19 from the Central Bank of Nigeria ( CBN) meant, as part of proactive measures to cushion the impact of COVID- 19 pandemic on the economy.

The Guardian learnt from the CBN that N93 billion of the Fund has already been disbursed to beneficiar­ies, repotedly no serious positive impact has also not been felt yet in the private sector as envisioned by the CBN. The interventi­on was with a view to strengthen­ing the sector’s capacity to meet potential increase in demand for healthcare products and services. Specifical­ly, the scheme was to provide credit to indigenous pharmaceut­ical companies and other healthcare value chain players to build or expand capacity. The Scheme is expected to increase private and public investment in the healthcare sector, facilitate improvemen­ts in healthcare delivery and reduce medical tourism to enhance foreign exchange conservati­on.

Chairman, Pharmaceut­ical Manufactur­ers Group of Manufactur­ers Associatio­n of Nigeria ( PMG- MAN), Dr. Fidelis Ayebae, told

The Guardian: “Every company that met the loan requiremen­t got it. We are happy with the CBN for the initiative and the way it was implemente­d. Members that are yet to access it are working with the commercial banks with whom they have a relationsh­ip to close up documentat­ion gaps before moving on to CBN. Overall it is success in interventi­on. Some of the impact can already

Emefiele be seen in the financial performanc­e of the early recipients of the loans.”

But a consultant pharmacist and medical director, Merit Healthcare, Dr. Lolu Ojo, disagrees. Ojo told The Guardian: “If not for the fact that we know of some big companies that got the money, we would have called the ‘ N100 billion interventi­on fund’ a ‘ 419’ scheme.

“Many companies have offer but no fund was released. We pestered the bank with release requests but they in turn blamed the CBN for the stalemate.

“The interventi­on fund is long on words and promises but ultra short on action and result delivery.”

President, Nigerian Associatio­n of Resident Doctors ( NARD), Dr. Uyilawa Okhuaihesu­yi, told The Guardian: “Federal government through the CBN had offered pharmaceut­ical companies and medical practition­ers low interest rate loans up to N100 billion from March 2020 as interventi­on to improve local manufactur­ing and increase their capacities to combat the ravaging COVID 19 pandemic and other related health challenges.

“Although there were laid down guidelines for obtaining the loan, we are not aware if interested and qualified doctor, hospitals/ organisati­ons were given the loan.

“No organisati­on or individual came to tell if they succeeded in pursuing the loan. More so, we are not aware if the guideline is a tight bottleneck that did or did not make the loan available or accessible. But certainly, the CBN will or should be able to give a

Ehanire Ohuabunwa data of those that were able to access the loan.”

But Acting Head, Corporate Affairs of the CBN, Mr. Osita Nwanisobi, disagrees. He said the Health Sector Interventi­on Facility ( HSIF) was establishe­d to address health infrastruc­ture decay in the country.

Nwanisobi said: “Over N85 billion has been disbursed to date covering 82 projects. N22.5 billion was disbursed to States for revamping of primary health care centres across the country.

“On monitoring, we are evaluating the utilisatio­n and thus far there has not been any diversion.

“We need to understand that this is a health interventi­on and the health sector is regulated. What you may refer to absence of evidence of investment in the sector is because the beneficiar­ies are doing the right thing by going through the regulatory hurdles for each stage of utilisatio­n. Soon the impact will be obvious. Besides, the CBN also carry out impact assessment of the facility.”

He said the HSIF has been used to finance the following: acquisitio­n and installati­on of 16 magnetic Resonance Imaging ( MRI) Machines across the country; and acquisitio­n and installati­on of 22 medical scanning machines by hospital across the country.

“These are verifiable and we confirm that they have been installed,” Nwanisobi said.

EANWHILE, pharmacist­s under the aegis of the Pharmaceut­ical Society of Nigeria ( PSN), last year, gave reasons why most of their members were yet to access the N100 billion COVID- 19 interventi­on fund for the healthcare/ pharmaceut­ical industry.

President, PSN, Mazi Sam Ohuabunwa, had told journalist­s: “The PSN has noted with pleasure that some healthcare/ pharmaceut­ical companies that applied for the special N100 billion CBN facility have been granted. Neverthele­ss, we are distressed that the majority of the applicants are yet to be successful.”

To address the situation, Ohuabunwa, therefore, asked for the expedition of the review and approval of many of the outstandin­g applicatio­ns so that the overall impact on industrial capacity, capability and output will be significan­tly enhanced in line with the noble objectives of the facility, especially as COVID- 19 pandemic subsists and the need for self- sufficienc­y in local drug production persists.

M“If not for the fact that we know of some big companies that got the money, we would have called the ‘ N100 billion interventi­on fund’ a ‘ 419’ scheme. “Many companies have offer but no fund was released. We pestered the bank with release requests but they in turn blamed the CBN for the stalemate. “The interventi­on fund is long on words and promises but ultra short on action and result delivery.”

 ??  ??
 ??  ??
 ??  ??
 ??  ??
 ??  ??

Newspapers in English

Newspapers from Nigeria